HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Emmeran Gams Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zimmermann, N. Articles by Scholz, H. Search for Related Content PubMed PubMed Citation Articles by Zimmermann, N. Articles by Scholz, H.

Eur J Cardiothorac Surg 1998;14:70-75
© 1998 Elsevier Science NL

Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?¹

^a Klinik für Thorax- und Kardiovaskuläre Chirurgie, Heinrich Heine-Universität, Moorenstrasse 5, D-40225 Düsseldorf, Germany
^b Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Domagkstrasse 12, D-48129 Münster, Germany
^c Ciba-Geigy Limited, Basle, Pharmaceuticals Division, Research and Development, CH-4002 Basle, Switzerland
^d Abteilung Allgemeine Pharmakologie, Universitäts-Krankenhaus Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany

Received 29 September 1997; received in revised form 15 April 1998; accepted 15 April 1998.

^* Corresponding author. Tel.:+49 211 8118331; fax: +49 211 8118333.

Objective: Due to shortage of donor hearts and increasing waiting-lists of patients with end-stage heart disease, new pharmacological principles for bridging therapies are necessary. The positive inotropic effects of cAMP-increasing drugs (e.g. catecholamines, phosphodiesterase-inhibitors) are diminished in the failing myocardium. Hence, we investigated the usefulness and mechanism of the two calcium sensitizers, levosimendan and CGP 48506 in preparations from end-stage failing human hearts since the exact mechanism of the positive inotropic effects is not yet clearly understood. Methods: Failing human hearts which required orthotopic heart transplantation due to idiopathic dilated cardiomyopathy were investigated. Contraction experiments were performed using muscle strips of ventricles. Calcium sensitization was investigated in skinned fibers and phosphodiesterase activity was measured in ventricular homogenate. In addition, cAMP levels were quantified in myocytes from guinea-pig hearts. Results: In muscle stripes from failing human hearts levosimendan (10 µmol/l) increased the force of contraction only to 112.8±6.7% of predrug values. In contrast, CGP 48506 increased the force of contraction to 311±59% of predrug values at 100 µmol/l. The time to peak tension and time of relaxation were increased to 175±4% and 205±15% of control levels at 100 µmol/l. Skinned fibers from failing human hearts were sensitized to calcium with an EC₅₀ of 10 µmol/l. Other mechanisms of action were excluded since CGP 48506 affected neither the activity of phosphodiesterase isoenzymes I–IV in failing human hearts, nor cAMP levels in guinea-pig cardiomyocytes. On the other hand, levosimendan (1 µmol/l) increased cAMP content from 6.3±0.3 to 8.1±0.3 pmol/mg protein. Conclusion: CGP 48506 is an inotropic agent with calcium-sensitizing properties in the human heart, that is devoid of inhibitory activity on human cardiac phosphodiesterase isoenzymes. It offers, therefore, a new form of positive inotropic therapy that can be useful for the bridging treatment of heart failure before transplantation. On the other hand, levosimendan is a calcium sensitizer showing less-effective inotropic effects accompanied by increased cAMP levels.

Key Words: Calcium sensitizer • CGP 48506 • Levosimendan • End-stage heart failure

This article has been cited by other articles:

				H. Tachibana, H.-J. Cheng, T. Ukai, A. Igawa, Z.-S. Zhang, W. C. Little, and C.-P. Cheng Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H914 - H922. [Abstract] [Full Text] [PDF]

				E du Toit, D Hofmann, J McCarthy, and C Pineda Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model Heart, July 1, 2001; 86(1): 81 - 87. [Abstract] [Full Text] [PDF]

				Q. Kleerekoper and J. A. Putkey Drug Binding to Cardiac Troponin C J. Biol. Chem., August 20, 1999; 274(34): 23932 - 23939. [Abstract] [Full Text] [PDF]